Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: A meta-analysis

Liver International

Volumn 28, Issue 1, 2008, Pages 28-38

  Martyak, Lenna A ^a   Taqavi, Ehsan ^a   Saab, Sammy ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Pfleger Liver Institute   (United States)

Author keywords

Chemotherapy; HBV; HBV prophylaxis; Hepatitis B reactivation; Lamivudine prophylaxis

Indexed keywords

ADEFOVIR; ANTHRACYCLINE; ANTIVIRUS AGENT; ENTECAVIR; LAMIVUDINE; STEROID;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DRUG EFFICACY; ETHNICITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; NEOPLASM; NONHUMAN; OVERALL SURVIVAL; PROPHYLAXIS; RISK REDUCTION; SEROLOGY; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; THERAPY DELAY; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION;

DATABASES, BIBLIOGRAPHIC; DRUG THERAPY; HEPATITIS B; HUMANS; LAMIVUDINE; RECURRENCE;

EID: 37449031759     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01618.x     Document Type: Article

References (40)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
2. McQuillan GM, Coleman PJ, Kruszon-Moran D, et al. Prevalence of hepatitis B virus infection in the United States: The national health and nutrition examination surveys, 1976 through 1994. Am J Public Health 1999; 89: 14-8.
3. Mast EE, Weinbaum CM, Fiore AE, et al. Advisory committee on immunization practices (ACIP) centers for disease control and prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the advisory committee on immunization practices (ACIP) part II: immunization of adults. MMWR Recomm Rep 2006; 55 (RR-16): 1-33.
4. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
5. Hoofnagle JH, Dusheiko GM, Schafer DF, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96: 447-9.
6. Steinberg JL, Yeo W, Zhong S, et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumors: Precore/ core mutations may play an important role. J Med Virol 2000; 60: 249-55.
7. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307.
8. Perry MC, Anderson CM, Doneower RC. Chemotherapy. In: Abeloff: Clinical Oncology, 3rd edn. Churchill, an Imprint of Elsevier 2004; 484-538.
9. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rates. Cancer Treat Rep 1979; 63: 1727-33.
10. Norton L, Simon R. Tumor size, sensitivity to therapy, and the design of treatment schedules. Cancer Treat Rep 1977; 61: 1307-17.
11. Lazarus HM, Vogelsang GB, Rowe JM. Prevention and treatment of acute graft-versus-host disease: The old and the new; a report from the eastern cooperative oncology group (ECOG). Bone Marrow Transplant 1997; 19: 577-600.
12. Sullivan KM, Storek J, Kopecky KJ, et al. Controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 1996; 2: 44-53.
13. Dai MS, Wu PF, Shyu RY, et al. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 2004; 24: 540-6.
14. Idilman R, Arat M, Soydan E, et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 2004; 11: 41-7.
15. Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006; 43: 233-40.
16. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-9.
17. Lee GW, Ryu MH, Lee JL, et al. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci 2003; 18: 849-54.
18. Lim LL, Wai CT, Lee YM, et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 2002; 16: 1939-44.
19. Nagamatsu H, Itano S, Nagaoka S, et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol 2004; 99: 2369-75.
20. Sugimoto R, Enjoji M, Kotoh K, et al. Effect of lamivudine for hepatitis B virus reactivation in blood cancer patients undergoing immunosuppressive chemotherapy. Fukuoka Igaku Zasshi 2004; 95: 274-9.
21. Yeo W, Ho WH, Hui P, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004; 88: 209-15.
22. Yeo W, Hui EP, Chan AT, et al. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol 2005; 28: 379-84.
23. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927-34.
24. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
25. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17: 1-12.
26. Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68.
27. Roche B, Samuel D, Gigou M, et al. De Novo and apparent de novo hepatitis B virus infection after liver transplantation. J of Hepatology 1997; 26: 517-26.
28. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 1276-82.
29. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.
30. Yao GB, Cui ZY, Wang BE, et al. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int 2004; 3: 188-93.
31. Lau GK, Leung YH, Fong DY, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HB reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic stem cell transplantation. Blood 2002; 99: 2324-30.
32. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-11.
33. Zhong S, Yeo W, Schroder C, Chan PK, et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing chemotherapy. J Viral Hepatitis 2004; 11: 55-9.
34. Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-72.
35. Seta T, Yokosuka O, Imazeki F, et al. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients. J Med Virol 2000; 60: 8-16.
36. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoin lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90.
37. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129-34.
38. Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101.
39. Xiong X, Flores C, Yang H, et al. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28: 1669-73.
40. Lai CL, Shouval D, Lok A, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J. Med 2006; 354: 1011-20.